Ken Griffin Sarepta Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 512,477 shares of SRPT stock, worth $9.64 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
512,477
Previous 330,300
55.16%
Holding current value
$9.64 Million
Previous $5.65 Million
74.84%
% of portfolio
0.0%
Previous 0.0%
Shares
33 transactions
Others Institutions Holding SRPT
# of Institutions
406Shares Held
83.7MCall Options Held
5.27MPut Options Held
5.94M-
Vanguard Group Inc Valley Forge, PA10.8MShares$203 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$194 Million0.04% of portfolio
-
State Street Corp Boston, MA5.3MShares$99.8 Million0.0% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.69MShares$50.5 Million0.49% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.65MShares$49.8 Million0.07% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $1.65B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...